Archana Prashanth1, Heather Donaghy1, Shihani P Stoner1, Amanda L Hudson1, Helen R Wheeler1,2, Connie I Diakos1,2, Viive M Howell1, Georges E Grau3, Kelly J McKelvey1. 1. Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia. 2. Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. 3. Vascular Immunology, Department of Pathology, School of Pathology, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia.
Abstract
BACKGROUND: High grade gliomas (HGG) are incapacitating and prematurely fatal diseases. To overcome the poor prognosis, novel therapies must overcome the selective and restricted permeability of the blood-brain barrier (BBB). This study critically evaluated whether in vitro human normal BBB and tumor BBB (BBTB) are suitable alternatives to "gold standard" in vivo models to determine brain permeability. METHODS: A systematic review utilizing the PRISMA guidelines used English and full-text articles from the past 5 years in the PubMed, Embase, Medline and Scopus databases. Experimental studies employing human cell lines were included. RESULTS: Of 1335 articles, the search identified 24 articles for evaluation after duplicates were removed. Eight in vitro and five in vivo models were identified with the advantages and disadvantages compared within and between models, and against patient clinical data where available. The greatest in vitro barrier integrity and stability, comparable to in vivo and clinical permeability data, were achieved in the presence of all cell types of the neurovascular unit: endothelial cells, astrocytes/glioma cells, pericytes and neurons. CONCLUSIONS: In vitro co-culture BBB models utilizing stem cell-derived or primary cells are a suitable proxy for brain permeability studies in order to reduce animal use in medical research.
BACKGROUND: High grade gliomas (HGG) are incapacitating and prematurely fatal diseases. To overcome the poor prognosis, novel therapies must overcome the selective and restricted permeability of the blood-brain barrier (BBB). This study critically evaluated whether in vitro human normal BBB and tumor BBB (BBTB) are suitable alternatives to "gold standard" in vivo models to determine brain permeability. METHODS: A systematic review utilizing the PRISMA guidelines used English and full-text articles from the past 5 years in the PubMed, Embase, Medline and Scopus databases. Experimental studies employing human cell lines were included. RESULTS: Of 1335 articles, the search identified 24 articles for evaluation after duplicates were removed. Eight in vitro and five in vivo models were identified with the advantages and disadvantages compared within and between models, and against patient clinical data where available. The greatest in vitro barrier integrity and stability, comparable to in vivo and clinical permeability data, were achieved in the presence of all cell types of the neurovascular unit: endothelial cells, astrocytes/glioma cells, pericytes and neurons. CONCLUSIONS: In vitro co-culture BBB models utilizing stem cell-derived or primary cells are a suitable proxy for brain permeability studies in order to reduce animal use in medical research.
Authors: Monica L Moya; Michael Triplett; Melinda Simon; Javier Alvarado; Ross Booth; Joanne Osburn; David Soscia; Fang Qian; Nicholas O Fischer; Kristen Kulp; Elizabeth K Wheeler Journal: Ann Biomed Eng Date: 2019-11-18 Impact factor: 3.934
Authors: O van Tellingen; B Yetkin-Arik; M C de Gooijer; P Wesseling; T Wurdinger; H E de Vries Journal: Drug Resist Updat Date: 2015-03-06 Impact factor: 18.500
Authors: B B Weksler; E A Subileau; N Perrière; P Charneau; K Holloway; M Leveque; H Tricoire-Leignel; A Nicotra; S Bourdoulous; P Turowski; D K Male; F Roux; J Greenwood; I A Romero; P O Couraud Journal: FASEB J Date: 2005-09-01 Impact factor: 5.191
Authors: Tyler D Brown; Maksymilian Nowak; Alexandra V Bayles; Balabhaskar Prabhakarpandian; Pankaj Karande; Joerg Lahann; Matthew E Helgeson; Samir Mitragotri Journal: Bioeng Transl Med Date: 2019-01-13
Authors: Caterina Brighi; Lee Reid; Laura A Genovesi; Marija Kojic; Amanda Millar; Zara Bruce; Alison L White; Bryan W Day; Stephen Rose; Andrew K Whittaker; Simon Puttick Journal: Theranostics Date: 2020-05-15 Impact factor: 11.556
Authors: Friedrich Erhart; Matthias Hackl; Hannes Hahne; Johanna Buchroithner; Chen Meng; Simone Klingenbrunner; René Reitermaier; Katrin Fischhuber; Susanna Skalicky; Walter Berger; Sabine Spiegl-Kreinecker; Daniela Lötsch; Gerda Ricken; Bernhard Kuster; Adelheid Wöhrer; Georg Widhalm; Johannes Hainfellner; Thomas Felzmann; Alexander M Dohnal; Christine Marosi; Carmen Visus Journal: NPJ Vaccines Date: 2020-01-16 Impact factor: 7.344
Authors: Arielly H Alves; Mariana P Nucci; Javier B Mamani; Nicole M E Valle; Eduarda F Ribeiro; Gabriel N A Rego; Fernando A Oliveira; Matheus H Theinel; Ricardo S Santos; Lionel F Gamarra Journal: Cancers (Basel) Date: 2022-02-09 Impact factor: 6.639